| Literature DB >> 27347553 |
Steven J Naoum1, Andrea Lenard1, F Elizabeth Martin1, Ayman Ellakwa1.
Abstract
Background. To assess the clinical efficacy of a dentifrice containing fluoride and functionalised tricalcium phosphate (fTCP) in reducing dentine sensitivity. Methods. A 10-week parallel blind randomised control trial was conducted. Subjects were assigned to one of four groups and instructed to brush twice daily: A: Colgate Cavity Protection (1000 ppmF-MFP); B: Sensodyne Total Care (1000 ppmF-NaF + 19300 ppmK(+)-KNO3); C: Clinpro Tooth Crème (950 ppmF-NaF + fTCP); and D: Clinpro Tooth Crème (brushing + additional topical application). Seventy-one patients were assessed at baseline, 6 weeks, and 10 weeks for cold, tactile, and hypertonic sensitivity using the NRS-11 pain rating scale. A combined modalities sensitivity score (CMS) was calculated. Results. At 6 weeks, patients reported the following reduction in CMS: A (20%); B (30%); C (42%); D (52%). At 10 weeks, patients reported the following reduction in CMS: A (18%), B (40%), C (24%), and D (54%). The only CMS comparisons to show a significant difference (P < 0.05) were between Groups A and D (6 and 10 weeks). Conclusions. Addition of fTCP to a dentifrice enhances the ability of dentifrice fluoride in reducing dentine sensitivity. Using Clinpro Tooth Crème twice daily for brushing can be as effective to reduce dentine sensitivity as twice daily brushing using Sensodyne Total Care. However, additional nightly topical application of fTCP, in addition to twice daily brushing, showed an enhanced reduction in dentine sensitivity.Entities:
Year: 2015 PMID: 27347553 PMCID: PMC4897285 DOI: 10.1155/2015/905019
Source DB: PubMed Journal: Int Sch Res Notices ISSN: 2356-7872
Figure 111-point Pain Numbered Rating Scale (NRS-11).
Study population and baseline sensitivity summary.
| Number of participants | Baseline sensitivity means (±SD) | |||||
|---|---|---|---|---|---|---|
| Mean age | Combined modalities sensitivity score | Evaporative (cold) sensitivity | Tactile sensitivity | Hypertonic (sweet) sensitivity | ||
| Group A | 20 | 45 | 2.93 (±2.30) | 4.14 (±2.84) | 2.50 (±3.02) | 2.17 (±2.89) |
| Group B | 17 | 39 | 3.09 (±1.92) | 4.89 (±2.25) | 1.95 (±2.55) | 2.42 (±2.72) |
| Group C | 16 | 39 | 2.28 (±1.53) | 3.79 (±2.26) | 1.63 (±2.31) | 1.40 (±2.08) |
| Group D | 18 | 40 | 2.89 (±2.22) | 4.49 (±2.70) | 1.86 (±2.65) | 2.33 (±2.83) |
Group A: Colgate Cavity Protection; Group B: Sensodyne Total Care; Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application).
Summary of changes in pain score (NRS-11) from baseline within each test group.
| 6-week score (Tx cessation) | 10-week score (4 weeks after Tx cessation) | |||
|---|---|---|---|---|
| Pain score adjusted means | % reduction from baseline | Pain score adjusted means | % reduction from baseline | |
| Group A | ||||
| Evaporative | 3.82 | 12% | 3.50 | 19% |
| Tactile | 1.60 | 26% | 2.14 | −6.10% |
| Hypertonic | 1.42 | 33% | 1.22 | 42% |
| CMS | 2.26 | 20% | 2.30 | 18% |
| Group B | ||||
| Evaporative | 3.51 | 19% | 2.97 | 31% |
| Tactile | 1.22 | 40% | 1.27 | 37% |
| Hypertonic | 1.24 | 41% | 0.92 | 56% |
| CMS | 1.97 | 30% | 1.69 | 40% |
| Group C | ||||
| Evaporative | 2.39 | 45% | 2.89 | 33% |
| Tactile | 1.11 | 32% | 1.74 | 14% |
| Hypertonic | 1.26 | 40% | 1.65 | 22% |
| CMS | 1.65 | 42% | 2.14 | 24% |
| Group D | ||||
| Evaporative | 2.48 | 43% | 2.46 | 43% |
| Tactile | 0.77 | 62% | 0.72 | 64% |
| Hypertonic | 0.83 | 61% | 0.73 | 66% |
| CMS | 1.35 | 52% | 1.29 | 54% |
Group A: Colgate Cavity Protection; Group B: Sensodyne Total Care; Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application). A positive value of percentage change indicates an improvement in sensitivity at the time of assessment compared to baseline.
CMS: combined modalities score is the average of all testing modalities, evaporative, tactile, and hypertonic.
Adjusted baseline means from ANCOVA: evaporative = 4.35; tactile = 2.00; hypertonic = 2.12; CMS = 2.83.
Figure 2Percent change in Evaporative (cold) sensitivity scores from baseline to 6 weeks (cessation of treatment) and 10 weeks (4 weeks after treatment cessation). Group A: Colgate Cavity Protection (negative control); Group B: Sensodyne Total Care (positive control); Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application). ∗ Scores significantly different from negative control (P < 0.05, 95% CI). ∗∗ Scores significantly different from both positive and negative control (P < 0.05, 95% CI).
Figure 3Percent change in tactile sensitivity scores from baseline to 6 weeks (cessation of treatment) and 10 weeks (4 weeks after treatment cessation). Group A: Colgate Cavity Protection (negative control); Group B: Sensodyne Total Care (positive control); Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application). ∗ Scores significantly different from negative control (P < 0.05, 95% CI). ∗∗ Scores significantly different from both positive and negative control (P < 0.05, 95% CI).
Figure 4Percent change in hypertonic (sweet) sensitivity scores from baseline to 6 weeks (cessation of treatment) and 10 weeks (4 weeks after treatment cessation). Group A: Colgate Cavity Protection (negative control); Group B: Sensodyne Total Care (positive control); Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application). ∗ Scores significantly different from negative control (P < 0.05, 95% CI). ∗∗ Scores significantly different from both positive and negative control (P < 0.05, 95% CI).
Figure 5Percent change in combined modalities sensitivity scores from baseline to 6 weeks (cessation of treatment) and 10 weeks (4 weeks after treatment cessation). Group A: Colgate Cavity Protection (negative control); Group B: Sensodyne Total Care (positive control); Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application). ∗ Scores significantly different from negative control (P < 0.05, 95% CI). ∗∗ Scores significantly different from both positive and negative control (P < 0.05, 95% CI).